Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 23 2024
0mins
Source: Benzinga
Stride, Inc. Financial Results: Stride, Inc. shares surged 24.3% in pre-market trading after reporting first-quarter earnings of 94 cents per share, significantly exceeding the analyst estimate of 20 cents, along with sales of $551.084 million surpassing expectations.
Stock Movements: Several stocks experienced notable pre-market movements, including CNS Pharmaceuticals rising 99.4%, DBV Technologies gaining 75.7%, and Alto Neuroscience dropping 61.4% following disappointing trial results.
Analyst Views on CNSP
Wall Street analysts forecast CNSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNSP is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.370
Low
20.00
Averages
20.00
High
20.00
Current: 7.370
Low
20.00
Averages
20.00
High
20.00
About CNSP
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
